Abbott announced that it will acquire St. Jude Medical in an effort to enhance its global scale and diversify its portfolio.
With the acquisition, Abbott will become a “premier medical device leader with top positioning in high-growth [CV] markets, including AF, structural heart and HF as well as a leading position in the high-growth neuromodulation market,” the company stated in a press release.
According to the release, St. Jude Medical’s strength in devices for cardiac rhythm management and treatment of HF and atrial fibrillation complements Abbott’s strength in devices for coronary intervention and transcatheter mitral valve repair, and will enable the combined company to compete in almost every facet of the CV market.
“The combined business will have a powerful pipeline ready to deliver next-generation medical technologies and offer improved efficiencies for health care systems around the world,” Miles D. White, chairman and CEO of Abbott, said in the release. The pipeline also includes products for diabetes, vision and neuromodulation, the company stated.
Full Content: The Wall Street Journal
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
DOJ and FTC Introduce Website for Reporting Anti-Competitive Healthcare Practices
Apr 18, 2024 by
CPI
US Congress Advances Legislation to Compel TikTok Sale
Apr 18, 2024 by
CPI
UK Financial Sector Advocates Enhanced Regulatory Accountability
Apr 18, 2024 by
CPI
Google and All 50 States Defend $700 Million Consumer Settlement
Apr 18, 2024 by
CPI
Colorado Enacts First Law to Protect Consumer Brainwave Data
Apr 18, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI